Abstract
Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.
Keywords: JNK, MAP kinase, SP600125, kinase inhibitor, mast cell, IgE, PI3K, allergy
Current Enzyme Inhibition
Title: Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Volume: 6 Issue: 1
Author(s): Shuhei Tanemura, Tokiwa Yamasaki, Toshiaki Katada and Hiroshi Nishina
Affiliation:
Keywords: JNK, MAP kinase, SP600125, kinase inhibitor, mast cell, IgE, PI3K, allergy
Abstract: Stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) belongs to the mitogen-activated protein kinase (MAPK) family and plays an important role in many biological contexts. JNK is deeply involved in several serious human disorders, including inflammation, obesity, diabetes, neuronal disease and cancer. Accordingly, JNK has been recognized as an appropriate target for the treatment of these diseases, and much effort has been expended over the past 15 years to isolate JNK inhibitors that can inactivate this kinase. In 2001, the compound SP600125 was reported as the first JNK-specific inhibitor. Many researchers have subsequently employed SP600125 in in vitro and in vivo models to evaluate whether certain disease-associated events are JNK-dependent. Indeed, more than 1300 studies citing the use of SP600125 as a JNK inhibitor in cell cultures and animal models have been reported. However, although SP600125 has been employed successfully to inhibit JNK in several situations, there have been questions about its specificity for JNK. SP600125 can bind to a broad range of protein kinases and inhibit some of them with similar or greater potency than JNK, confirming that many additional kinases may be targets of SP600125. In this article, we review both the usefulness of SP60125 as a JNK inhibitor and the limitations to its specificity.
Export Options
About this article
Cite this article as:
Tanemura Shuhei, Yamasaki Tokiwa, Katada Toshiaki and Nishina Hiroshi, Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase, Current Enzyme Inhibition 2010; 6(1) . https://dx.doi.org/10.2174/157340810790712023
DOI https://dx.doi.org/10.2174/157340810790712023 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Relationships Between Alcohol Consumption, Smoking Status and Food Habits in Greek Adolescents. Vascular Implications for the Future
Current Vascular Pharmacology Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Advances of Mesenchymal Stem Cells Derived from Bone Marrow and Dental Tissue in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Radiological Assessment of Giant Cell Tumour of Bone in the Sacrum: From Diagnosis to Treatment Response Evaluation
Current Medical Imaging Update on Sirolimus Drug-Eluting Stents
Current Pharmaceutical Design High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Update on the Imaging Techniques in the Diagnosis of Diabetic Retinopathy
Current Diabetes Reviews Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine The Intriguing Occurrence of Segmental Arterial Mediolysis: Case Report and Concise Literature Review
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections
Recent Patents on Medical Imaging (Discontinued) The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Intracranial Aneurysms; In Need of Early Diagnostic and Treatment Using Bio- and Nanotechnology
Current Medicinal Chemistry Ruptured Bronchial Artery Aneurysm Treated With Aortic Stent Graft and Aneurysm Embolization
Current Medical Imaging Neurotoxicity: The Broad Framework of Electron Transfer, Oxidative Stress and Protection by Antioxidants
Current Medicinal Chemistry - Central Nervous System Agents